Literature DB >> 7257959

Metal binding by pharmaceuticals. Part 1. Copper(II) and zinc(II) interactions following ethambutol administration.

A Cole, P M May, D R Williams.   

Abstract

Formation constants for copper(II) and zinc(II) complexes of dextro-2,2'-(ethylenediimino)-di-1-butanol (ethambutol) and its metabolic oxidation product, 2,2'-(ethylenediimino)-dibutyric acid (EDBA) have been measured potentiometrically at 37 degrees C, I = 0.15 mol dm-3 [NaCl]. The constants are used in computer models to assess the extent of the formation of these complexes in vivo. These simulations indicate that whereas ethambutol forms metal complexes only to a limited extent in vivo, EDBA competes effectively under physiological conditions for copper(II) and zinc(II). This study suggests that zinc(II) binding by EDBA may account for a number of side effects of ethambutol treatment.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7257959     DOI： 10.1007/bf01967631

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  22 in total

1.  THE ABSORPTION, EXCRETION, AND METABOLIC FATE OF ETHAMBUTOL IN MAN.

Authors:  E A PEETS; W M SWEENEY; V A PLACE; D A BUYSKE
Journal:  Am Rev Respir Dis       Date:  1965-01

2.  Ocular zinc concentration.

Authors:  M A GALIN; H D NANO; T HALL
Journal:  Invest Ophthalmol       Date:  1962-02

3.  Metal chelates and antitubercular activity. III. p-Aminosalicylic acid: chelate vs. complex.

Authors:  W O FOYE; R N DUVALL
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1958-04

4.  Computer calculation of equilibrium constants of species present in mixtures of metal ions and complexing agents.

Authors:  I G Sayce
Journal:  Talanta       Date:  1968-12       Impact factor: 6.057

5.  Computer simulation of chelation therapy. Plasma mobilizing index as a replacement for effective stability constant.

Authors:  P M May; D R Williams
Journal:  FEBS Lett       Date:  1977       Impact factor: 4.124

6.  Pharmacological and biochemical studies on ethambutol in laboratory animals.

Authors:  D A Buyske; E Peets; W Sterling
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

Review 7.  Ethambutol: a review with special reference to ocular toxicity.

Authors:  K M Citron
Journal:  Tubercle       Date:  1969-03

8.  Metabolic and special studies of ethambutol in normal volunteers and tuberculous patients.

Authors:  V A Place; E A Peets; D A Buyske; R R Little
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

9.  Ethambutol-mediated alterations in ribonucleic acid components of Mycobacterium smegmatis.

Authors:  J Bacalao; M Rieber
Journal:  J Bacteriol       Date:  1972-11       Impact factor: 3.490

10.  EFFECT OF ETHAMBUTOL ON CYTOLOGY OF MYCOBACTERIUM SMEGMATIS.

Authors:  G R GALE; H H MCLAIN
Journal:  J Bacteriol       Date:  1963-10       Impact factor: 3.490
View more
  8 in total

Review 1.  Iron supplements: a common cause of drug interactions.

Authors:  N R Campbell; B B Hasinoff
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

2.  Effects of folic acid and amino acids supplementation on zinc intestinal absorption in the progeny of ethanol-treated rats.

Authors:  E Tavares; O Carreras; A Gómez-Tubío; D Murillo; M L Murillo
Journal:  J Physiol Biochem       Date:  2000-09       Impact factor: 4.158

3.  Exploration of the Plausible Mechanism of Ethambutol Induced Ocular Toxicity by Using Proteomics Informed Physiologically Based Pharmacokinetic (PBPK) Modeling.

Authors:  Ankit Balhara; Mayur K Ladumor; Rakesh P Nankar; Samiulla Dodheri Syed; Sanjeev Giri; Bhagwat Prasad; Saranjit Singh
Journal:  Pharm Res       Date:  2022-03-17       Impact factor: 4.200

4.  An assessment of the physiological significance of cimetidine interactions with copper and zinc in biofluids as based on the computer-simulated distribution of the involved complexes at therapeutic levels of the drug.

Authors:  F Akrivos; M J Blais; J Hoffelt; G Berthon
Journal:  Agents Actions       Date:  1984-12

5.  Metal binding by pharmaceuticals. Part 3. Copper (II) and zinc (II) interactions with isoniazid.

Authors:  A Cole; P M May; D R Williams
Journal:  Agents Actions       Date:  1983-02

6.  Metal ion-tetracycline interactions in biological fluids. Part 5. Formation of zinc complexes with tetracycline and some of its derivatives and assessment of their biological significance.

Authors:  M Brion; L Lambs; G Berthon
Journal:  Agents Actions       Date:  1985-12

7.  Metal binding by pharmaceuticals. Part 5. Interaction of Cd(II), Ni(II) and Pb(II) with the intracellular hydrolysis products of the anti-tumour agent ICRF 159 and its inactive homologue ICRF 192.

Authors:  P M May; M J Willes; D R Williams; A M Creighton
Journal:  Agents Actions       Date:  1984-10

8.  Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192.

Authors:  Z X Huang; P M May; K M Quinlan; D R Williams; A M Creighton
Journal:  Agents Actions       Date:  1982-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.